6/17/2023 0 Comments Download two point studioHere in a phase I trial of adjuvant autogene cevumeran, an individualized neoantigen vaccine based on uridine mRNA–lipoplex nanoparticles, we synthesized mRNA neoantigen vaccines in real time from surgically resected PDAC tumours. Pancreatic ductal adenocarcinoma (PDAC) is lethal in 88% of patients 1, yet harbours mutation-derived T cell neoantigens that are suitable for vaccines 2, 3. Nature volume 618, pages 144–150 ( 2023) Cite this article Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer
0 Comments
Leave a Reply. |